SCHEMBL5440503

SCHEMBL5440503

CC(=O)Nc1cccc(Nc2nccc3c(-c4cccc(O)c4)cccc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 6/20 0.54
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.50
FYN P06241 3/20 0.49
BRAF P15056 4/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PLK1 P53350 1/20 0.47
ABCB1 P08183 1/20 0.47
ABCC1 P33527 1/20 0.47
RAF1 P04049 1/20 0.46
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
EGFR P00533 2/20 0.44
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437465 0.89 BRAF (0.45) ABCG2MEN1MAPTKMT2ABRAF
SCHEMBL5450861 0.83 ABCG2 (0.53) ABCG2MEN1MAPTKMT2ABRAF
SCHEMBL5455869 0.83 MEN1 (0.56) ABCG2KDM4EMEN1MAPTKMT2A
SCHEMBL5448685 0.82 BRAF (0.49) ABCG2MEN1MAPTKMT2ABRAF
SCHEMBL5442716 0.81 ABCG2 (0.59) ABCG2MEN1KMT2AMAPK1CYP1A2
SCHEMBL5449527 0.81 BRAF (0.46) ABCG2MEN1MAPTKMT2ABRAF
SCHEMBL5489174 0.80 BRAF (0.39) ABCG2BRAFHTTRAF1
SCHEMBL5441105 0.79 IKBKB (0.47) ABCG2BRAFRAF1SYK
SCHEMBL5450866 0.79 BRAF (0.50) MEN1KMT2AALDH1A1BRAFHTT
SCHEMBL5437478 0.76 ABCG2 (0.48) ABCG2MEN1MAPTKMT2ABRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US claimed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 ABCG2 1594/4885KDM4E 1569/4885MEN1 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.